Global Alzheimer’s Disease Therapeutics Market (By Drug Class, Route of Administration, Distribution Channel, and Region), Company Profiles, Recent Developments and Market Dynamics - Forecast to 2030

The global Alzheimer’s disease therapeutics market was valued at USD 4,655.1 Million in 2024, and the market is projected to reach USD 11,866.3 Million by 2030. Alzheimer’s disease is a chronic brain condition that frequently leads to dementia in older individuals. It affects memory, cognitive function, and disrupts daily routines. As the global population ages, the number of people diagnosed with Alzheimer’s disease continues to increase. For instance, according to Alzheimer's Association research published in 2023, an estimated 6.7 million Americans aged 65 and older had Alzheimer's disease, with the figure expected to rise to 13.8 million by 2060. Thus, the risk of Alzheimer’s increases with age, making it more common in the elderly population.

Alzheimer’s has become the leading cause of death among neurodegenerative diseases and a significant factor contributing to physical disability, necessitating urgent medical intervention. Traditionally, therapeutic approaches have centred on alleviating cognitive and functional symptoms to maintain patient quality of life. Over the past decade, the treatment landscape has expanded substantially from long-standing symptomatic therapies to emerging disease-modifying treatments (DMTs) designed to intervene across both early and advanced stages of the disease. For instance, the FDA approved Eisai / Biogen’s Leqembi (lecanemab) in January 2023 and Lilly’s Kisunla (donanemab) in July 2024, and both drugs have since been approved in Japan, China, and the UK. The adoption of these therapies is increasingly enabled by advances in diagnostic technologies, rising patient and caregiver awareness, and targeted health-system investments that support earlier detection and more personalized models of care.

Cholinesterase inhibitors and NMDA receptor antagonists continue to serve as the foundational therapies for symptomatic management in Alzheimer’s disease, supported by well-established efficacy profiles, comprehensive clinical guidelines, and broad availability through generic formulations. However, the therapeutic landscape is undergoing a significant shift toward biologic modalities. Biologics offer a more precise treatment approach. They focus on specific biological mechanisms involved in Alzheimer’s. This is leading to more biologics entering clinical trials. Early-stage candidates are demonstrating encouraging preliminary outcomes. As evidence accumulates and clinical performance improves, market sentiment is expected to increasingly favor biologic therapies, positioning them as the future growth engine of the Alzheimer’s therapeutics market.

Recent Developments

• In June 2025, Cure Parkinson and Alzheimer’s Research UK entered into a strategic partnership to capitalize on shared research findings, expertise and resources to accelerate drug development for both the diseases.
• In April 2025, Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted Marketing Authorization (MA) for Leqembi (lecanemab), an amyloid-beta (Aβ) monoclonal antibody, in the European Union (EU). This marks Leqembi as the first therapy targeting the underlying cause of Alzheimer’s disease (AD) to receive MA approval in the EU.
• In March 2025, Alpha Cognition Inc. launched ZUNVEYL (Benzgalantamin), that is the first oral FDA approved treatment which is meant to be indicated for mild to moderate Alzheimer’s disease.

Key Highlights of the Report

• In terms of drug class, Cholinesterase inhibitors remain the leading drug class in the global Alzheimer’s disease therapeutics market, commanding a significant share due to their established efficacy in treating mild to moderate stages of the disease. These drugs, including donepezil, galantamine, and rivastigmine, work by inhibiting the breakdown of acetylcholine in the brain, thereby supporting cognitive functions.
• NMDA receptor antagonists represent a crucial segment, primarily used in moderate to severe Alzheimer’s cases to regulate glutamate activity and provide symptomatic relief.
• Combination drug therapies, although smaller in share are gaining traction by pairing cholinesterase inhibitors with NMDA receptor antagonists in single formulations. These combinations improve patient convenience, adherence, and clinical outcomes by targeting multiple pathways simultaneously.
• The Disease-modifying therapies (DMTs) are rapidly reshaping the market by targeting Alzheimer's underlying pathology rather than symptoms alone. Monoclonal antibodies like lecanemab and donanemab, addressing amyloid and tau proteins, are establishing the DMT as the fastest-growing segment within the Alzheimer’s disease therapeutics market.
• Based on route of administration, the oral route remains the largest segment in the global Alzheimer’s disease therapeutics market. Oral medications are generally easier to administer than other forms of treatment, such as injections or infusions. This convenience improves patient compliance, as taking a pill is less intrusive and more manageable for daily routines, especially important in the elderly population who may have multiple comorbidities and medications.
• The intravenous (IV) route of administration represents a rapidly growing segment. IV therapies, including monoclonal antibodies like lecanemab and donanemab, offer precise drug delivery, crucial for targeting amyloid plaques and tau proteins in more advanced stages of Alzheimer’s. These treatments are typically administered in specialized centers requiring clinical oversight, contributing to the segment’s growth.
• The transdermal patch segment is rapidly carving its niche by providing a non-invasive, steady drug delivery system beneficial for elderly patients who have difficulty swallowing pills. Recent regulatory approvals and product launches, such as Corium’s once-weekly donepezil patch and Luye Pharma's rivastigmine patch, have boosted this segment.
• Based on distribution channel, Hospital pharmacies command the largest share in the global Alzheimer’s disease therapeutics market. Hospital pharmacies provide centralized management of medications, ensuring that Alzheimer’s patients receive their prescribed drugs accurately and on time. This centralized control helps in maintaining consistent medication regimens, which is crucial for managing a chronic condition like Alzheimer’s.
• Retail pharmacies serve as the primary access point for patients with mild to moderate Alzheimer’s, dispensing widely prescribed symptomatic medications such as cholinesterase inhibitors and NMDA receptor antagonists. The segment has evolved with the introduction of generic drugs enhancing affordability and expanded support programs aimed at improving medication adherence.
• Online pharmacies are an emerging segment in the global Alzheimer’s disease therapeutics market. These platforms offer unparalleled convenience by delivering medications directly to patients’ homes, particularly benefiting those in remote locations or with mobility challenges.
• On regional basis, North America dominates the global Alzheimer's disease therapeutics market. The region's dominance is driven by the rapidly aging population, extensive research and development initiatives, and substantial government investments supporting innovative drug discovery and early diagnosis.
• Europe accounted for second largest share of the Alzheimer's disease therapeutics market in 2024. This growth is propelled by Europe's rapidly aging population, where around 9 million EU residents are expected to have dementia by 2030, amplifying demand for innovative treatments amid rising prevalence.
• The Asia Pacific region is recognized as the fastest-growing Alzheimer's therapeutics market. Growth drivers include a rapidly expanding elderly population, increasing disease prevalence, and rising domestic biopharmaceutical investments in countries like Japan, China, and India.
• The Middle East & Africa Alzheimer's disease therapeutics market is propelled by a rising elderly population and improved healthcare access in key countries like Saudi Arabia, UAE, and Qatar.

Apelo Consulting report titled “Global Alzheimer’s Disease Therapeutics Market (By Drug Class, Route of Administration, Distribution Channel, and Region), Company Profiles, Recent Developments and Market Dynamics - Forecast to 2030” provides a complete assessment of the fast–evolving, high–growth Global Alzheimer’s Disease Therapeutics Market landscape.





This 90 Pages report with 26 Figures and 8 Tables has been analyzed from 9 pointers:

1) Global – Alzheimer’s Disease Therapeutics Market and Forecast (2021 – 2030)

2) Global – Alzheimer’s Disease Therapeutics Market Share and Forecast (2021 – 2030)

3) By Drug Class – Global Alzheimer’s Disease Therapeutics Market and Forecast (2021 – 2030)

4) By Route of Administration – Global Alzheimer’s Disease Therapeutics Market and Forecast (2021 – 2030)

5) By Distribution Channel – Global Alzheimer’s Disease Therapeutics Market and Forecast (2021 – 2030)

6) By Region – Global Alzheimer’s Disease Therapeutics Market and Forecast (2021 – 2030)

7) Global Alzheimer’s Disease Therapeutics Market – Company Profiles

8) Global Alzheimer’s Disease Therapeutics Market – Recent Developments

9) Global Alzheimer’s Disease Therapeutics – Market Dynamics

Global Alzheimer’s Disease Therapeutics Market – By Drug Class

1. Cholinesterase inhibitors

2. NMDA receptor antagonist

3. Combination drugs

4. DMT

Global Alzheimer’s Disease Therapeutics Market – By Route of Administration

1. Oral

2. Intravenous

3. Transdermal Patch

Global Alzheimer’s Disease Therapeutics Market – By Distribution Channel

1. Hospital Pharmacy

2. Retail Pharmacy

3. Online Pharmacy

Global Alzheimer’s Disease Therapeutics Market – By Region

1. North America

2. Europe

3. Asia Pacific

4. Latin America

5. MEA

Global Alzheimer’s Disease Therapeutics Market – Company Profiles

1. AbbVie, Inc.

2. Amgen, Inc.

3. AstraZeneca

4. Biogen Inc.

5. Cipla Ltd.

6. Daiichi Sankyo Company, Ltd.

7. Eisai Co., Ltd.

8. Eli Lilly and Company

9. H.Lundbeck A/S

10. Merck & Co., Inc.

11. Novartis AG

12. Pfizer Inc.

13. Sanofi

14. Sun Pharmaceutical Industries Ltd.

Data Source

Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise. Show more